CN108159390A - A kind of powder containing tannalbin - Google Patents
A kind of powder containing tannalbin Download PDFInfo
- Publication number
- CN108159390A CN108159390A CN201611149171.6A CN201611149171A CN108159390A CN 108159390 A CN108159390 A CN 108159390A CN 201611149171 A CN201611149171 A CN 201611149171A CN 108159390 A CN108159390 A CN 108159390A
- Authority
- CN
- China
- Prior art keywords
- tannalbin
- grain size
- powder containing
- powder
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Immunology (AREA)
Abstract
The invention discloses a kind of powders containing tannalbin, are less than 35 μm by the grain size for controlling wherein tannalbin, shorten its residence time in stomach, arrive at enteron aisle faster and play curative effect.
Description
Technical field
The present invention relates to a kind of powders containing tannalbin.
Background technology
Tannalbin is antidiarrheal agent, suitable for acute gastroenteritis and various Non-bacterial diarrheas, children's indigestion etc.；Tan
Acid albumin decomposes after taking orally through trypsase in the intestine, slowly releases tannic acid, makes the protein precipitation in intestinal mucosa surface layer, shape
Mitigate stimulation into layer protecting film, reduce inflammation penetrant and reduce enterocinesia, play astringing to arrest diarrhea.Tannalbin pair is made
With less, antidiarrheal effect is good, is clinically widely used.
Tannalbin does not decompose in stomach, plays a role until small intestine decomposites tannic acid, taking to action needs certain time.
Invention content
The invention discloses a kind of powders containing tannalbin, by controlling the size of tannalbin grain size, shorten it
In the residence time of stomach, enteron aisle is arrived at faster and plays curative effect.
Powder disclosed by the invention containing tannalbin, the wherein grain size of tannalbin are less than 35 μm.The tannic acid egg
White powder can contain only tannalbin, can also add in such as other ingredients of yeast, glucose.
Further, the grain size of tannalbin is less than 15 μm.Further, the grain size of tannalbin is 1-15 μm.
The powder containing tannalbin can nitrogen-filled packaging, effectively avoid powder particle aggregation obtained, control packet
Moisture and oxygen content in dress can reach preferably storage effect.
Tannalbin does not absorb after taking orally in stomach, is decomposed after arriving at enteron aisle through trypsase, slowly releases tannic acid, make
Protein precipitation in intestinal mucosa surface layer forms layer protecting film and mitigates stimulation, reduces inflammation penetrant and reduces enterocinesia,
So as to play the effect of astringing to arrest diarrhea, therefore longer time is needed from taking to action.It is had been surprisingly found that in inventor's research, when
When the grain size of tannalbin is less than 35 μm, tannalbin can arrive at enteron aisle by stomach faster, shorten onset time, faster
Curative effect is played, there is certain clinical advantage.
Specific embodiment
The above of the present invention is described in further detail again below by way of specific embodiment.But this should not be managed
It solves and is limited only to following example for the range of the above-mentioned theme of the present invention.In the situation for not departing from the above-mentioned technological thought of the present invention
Under, the various replacements or change made according to ordinary skill knowledge and customary means should all be included in model of the invention
In enclosing.
Embodiment 1
Prescription (100 bags)：
Tannalbin 10g (grain size D90：32.3μm)
Preparation method：Tannalbin is crushed to grain size D90 less than 35 μm, and 0.1g often wraps packing.(use Micros ultrafine crushers
It crushes, the detection of 2000 laser particle analyzer of grain size application Malvern)
Embodiment 2
Prescription (100 bags)：
Tannalbin 10g (grain size D90：14.2μm)
Preparation method：Tannalbin is crushed to grain size D90 less than 15 μm, and 0.1g often wraps packing.
Embodiment 3
Prescription (100 bags)：
Tannalbin 10g (grain size D90：1.1μm)
Preparation method：Tannalbin is crushed to grain size D90 less than 3 μm, and 0.1g often wraps packing.
Embodiment 4
Prescription (100 bags)：
Tannalbin 10g (grain size D90：0.4μm)
Preparation method：Tannalbin is crushed to grain size D90 less than 1 μm, and 0.1g often wraps packing.
Embodiment 5
Prescription (100 bags)：
Tannalbin 10g (grain size D90：28μm)
Yeast 10g
Preparation method：Tannalbin crushes, and is uniformly mixed with yeast, packing is often wrapped by tannalbin 0.1g.
Embodiment 6
Prescription (100 bags)：
Tannalbin 10g (grain size D90：10μm)
Yeast 10g
Glucose 10g
Preparation method：Tannalbin crushes, and is uniformly mixed with yeast, glucose, packing is often wrapped by tannalbin 0.1g.
Embodiment 7
Prescription (100 bags)：
Tannalbin 10g (grain size D90：0.2μm)
Yeast 10g
Glucose 10g
Preparation method：Tannalbin crushes, and is uniformly mixed with yeast, glucose, packing is often wrapped by tannalbin 0.1g.
Embodiment 8
1 sample nitrogen-filled packaging of embodiment, oxygen content 1.3%, water content 0.4%.
Embodiment 9
2 sample nitrogen-filled packaging of embodiment, oxygen content 0.9%, water content 0.8%.
Embodiment 10
Implement 3 sample nitrogen-filled packagings, oxygen content 1.2%, water content 0.7%.
Embodiment 11
4 sample nitrogen-filled packaging of embodiment, oxygen content 1.3%, water content 0.5%.
Embodiment 12
6 sample nitrogen-filled packaging of embodiment, oxygen content 0.9, water content 0.7%.
The analysis test result of tannalbin powder prepared by above example of the present invention：
(1) powder containing tannalbin prepared by above example is light brown or pale yellow powder, odorless, tasteless.
(2) tannalbin powder reaches the time of enteron aisle：3 monthly age mouse, every group 50, fasting state (going on a hunger strike for 24 hours) administration is pressed
Tannalbin meter 1g, Fixed Time Interval dissection mouse (5) recycle tannalbin in stomach, and statistics tannalbin enters enteron aisle
Up to the average time of total amount 1/2.Result of the test is shown, is shorter than the time required to the powder containing tannalbin prepared by embodiment
Reference preparation refers to the (reference preparation 1 of table 1：It is magnanimous come woods tannalbin dissipate HaiNan Kangzhi Pharmaceutical Co., Ltd grain size D90：
101.7μm；Reference preparation 2：Du Lailin tannalbin yeast dissipates HaiNan Kangzhi Pharmaceutical Co., Ltd grain size D90：104.6μ
m)
(3) stability result is shown：Reference preparation and embodiment sample are placed in 40 DEG C of high temperature, and 75% condition of humidity is placed, during June
It detects its grain size and reaches the enteron aisle time, evaluate its stability.The stability of most of embodiment sample is fine, but grain size is less than
At 0.1 μm, clustering phenomena is more apparent, is not sufficiently stable.Concrete outcome see the table below 1.
Table 1
Claims (9)
1. a kind of powder containing tannalbin, it is characterised in that：The grain size of the tannalbin is less than 35 μm.
2. the powder containing tannalbin as described in claim 1, it is characterised in that：The grain size of the tannalbin is less than 15
μm。
3. the powder containing tannalbin as described in claim 1, it is characterised in that：The grain size of the tannalbin is 1-15
μm。
4. the powder containing tannalbin as described in claim 1-3, it is characterised in that：It is made of tannalbin.
5. the powder containing tannalbin as described in claim 1-3, it is characterised in that：Its component includes tannalbin, ferment
It is female.
6. the powder containing tannalbin as claimed in claim 5, it is characterised in that：Its component further includes glucose.
7. the powder containing tannalbin as described in claim 1-3, it is characterised in that：The tannalbin powder is nitrogen charging
Packaging.
8. the powder containing tannalbin as claimed in claim 7, it is characterised in that：The tannalbin powder water content is small
In 1%.
9. the powder containing tannalbin as claimed in claim 7, it is characterised in that：Oxygen content is low in the nitrogen-filled packaging
In 2%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611149171.6A CN108159390A (en) | 2016-12-07 | 2016-12-07 | A kind of powder containing tannalbin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611149171.6A CN108159390A (en) | 2016-12-07 | 2016-12-07 | A kind of powder containing tannalbin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108159390A true CN108159390A (en) | 2018-06-15 |
Family
ID=62527156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611149171.6A Pending CN108159390A (en) | 2016-12-07 | 2016-12-07 | A kind of powder containing tannalbin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108159390A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1689639A (en) * | 2004-04-27 | 2005-11-02 | 合肥霄云科技有限公司 | Tannalbin rapid disintegration preparation and preparing method thereof |
| CN102552871A (en) * | 2011-12-13 | 2012-07-11 | 海南康芝药业股份有限公司 | Albumin tannate and yeast chewable tablet and production method thereof |
-
2016
- 2016-12-07 CN CN201611149171.6A patent/CN108159390A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1689639A (en) * | 2004-04-27 | 2005-11-02 | 合肥霄云科技有限公司 | Tannalbin rapid disintegration preparation and preparing method thereof |
| CN102552871A (en) * | 2011-12-13 | 2012-07-11 | 海南康芝药业股份有限公司 | Albumin tannate and yeast chewable tablet and production method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 任华益主编: "《实用药品名称用途用法用量速查手册》", 31 January 2007 * |
| 王宝琹主编: "《中成药质量标准与标准物质研究》", 31 March 1994 * |
| 陆彬主编: "《药剂学》", 31 January 2003 * |
| 陈琼主编: "《中药制剂技术（中药类相关专业用）》", 31 August 2009 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2479313C2 (en) | Method of treating and preventing respiratory diseases involving administration of cholecalciferol | |
| Mortaz et al. | Nutritional impact and its potential consequences on COVID-19 severity | |
| AU2017253087A1 (en) | Compositions and methods for improved restoration and preservation of the integrity of tissue barriers | |
| Umrani et al. | Jasada bhasma, a zinc‐based Ayurvedic preparation: contemporary evidence of antidiabetic activity inspires development of a Nanomedicine | |
| Maheshwari et al. | Preparation and pharmacological evaluation of silibinin liposomes | |
| Cai et al. | Radix Pseudostellariae protein-curcumin nanocomplex: improvement on the stability, cellular uptake and antioxidant activity of curcumin | |
| WO2021154774A1 (en) | Joint health composition and use thereof in healthy mammals | |
| Orazizadeh et al. | The effect of glycyrrhizin acid on Bax and Bcl2 expression in hepatotoxicity induced by Titanium dioxide nanoparticles in rats | |
| JP2017523983A (en) | Delivery of bioactive, nanoencapsulated antioxidants | |
| CN108159390A (en) | A kind of powder containing tannalbin | |
| El-Kott | Amelioration of nitrateinduced hepatotoxicity | |
| CN106729719B (en) | The medical composition and its use for treating helicobacter pylori infections | |
| US20160015691A1 (en) | Use of mtor inhibitors for prevention of neuroendocrine tumor development and growth | |
| Seo et al. | Antidiabetic activity of nanopowdered chitosan in db/db mice | |
| Birangane et al. | A review of antioxidants | |
| KR20220130733A (en) | Gold clusters (AuCs) and compositions for the treatment of liver cirrhosis | |
| CN106822097A (en) | A kind of pharmaceutical composition containing orlistat for losing weight | |
| EP1283045B1 (en) | Drug and food containing glucomannan for inhibiting IgE antibody | |
| Abdu et al. | Anti-inflammatory effect of Melittin on Mice Jejunum | |
| CN105310985B (en) | A kind of pharmaceutical composition and its preparation method and application | |
| Herdiana et al. | Nanoparticle-Based Antioxidants in Stress Signaling and Programmed Cell Death in Breast Cancer Treatment | |
| Al-Nadaf et al. | Juglans regia L. fruit pellicle extract-based bioreduction of silver nanoparticles: structural features and in vivo therapeutic effects against ethanol-induced peptic ulcers | |
| Alansari | Impact of Code Red energy drink on the functions and structure of the kidney of Wistar Albino rats: possible therapeutic effects of blueberry ethanolic extract | |
| CN104825730B (en) | A kind of Chinese medicine preparation and the purposes in the drug for preparing prevention or treatment lichen planus of mouth | |
| Singh et al. | In vitro-in vivo-in silico simulation of experimental design based optimized curcumin loaded multiparticulates system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180615 |
|
| WD01 | Invention patent application deemed withdrawn after publication |